Synlogic, Inc. (SYBX)

Market Cap	13.80M
Revenue (ttm)	n/a
Net Income (ttm)	2.56M
Shares Out	11.70M
EPS (ttm)	0.21
PE Ratio	5.63
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	18,827
Open	1.250
Previous Close	1.200
Day's Range	1.180 - 1.250
52-Week Range	0.898 - 1.880
Beta	0.55
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 7, 2025

About SYBX

Synlogic, Inc., a biopharmaceutical company, engages in the discovery and development of synthetic biotics to treat metabolic diseases in the United States. Its pipeline include SYNB1618 for the treatment of phenylketonuria; SYNB1353, an orally administered, non-systemically absorbed drug candidate, which is in Phase I clinical to treat homocystinuria; SYNB8802, an orally administered, non-systemically absorbed drug candidate for the treatment of enteric hyperoxaluria; and SYNB2081 to lower uric acid for the potential treatment of gout. The com...

• Industry: Biotechnology
• Sector: Healthcare
• CEO: Mary Dooley
• Employees: 1
• Stock Exchange: NASDAQ
• Ticker Symbol: SYBX
• Website: https://www.synlogictx.com

Financial Performance

In 2024, Synlogic's revenue was $8,000, a decrease of -99.76% compared to the previous year's $3.37 million. Losses were -$23.36 million, -61.88% less than in 2023.